CONFERENCE ABSTRACT ANNOUNCEMENT
American Society of Nephrology (ASN) Kidney Week 2026 · Denver, CO · October 21–25, 2026

RELIANT Glycosciences
Biomarkers for IgA Nephropathy™

PRESS RELEASE

Reliant Glycosciences Highlights Growing Use of GalD Assay® at ASN Kidney Week 2026

Birmingham, AL / October 2026

Reliant Glycosciences is pleased to share that research using its GalD Assay® will be featured in four abstracts at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, October 21–25. The abstracts come from research teams at four institutions across North America and Asia and from the NIH-sponsored Cure Glomerulonephropathy Network (CureGN), a multicenter research consortium, each presenting its own work on galactose-deficient IgA1 (Gd-IgA1) in IgA nephropathy (IgAN). This includes an external validation of the assay by the nephrology testing laboratory at Cincinnati Children's Hospital Medical Center.

Presenting institutions include University of Michigan Medicine with CureGN (TH-PO0462), Cincinnati Children's Hospital Medical Center (TH-PO0451), Ohio State University (TH-PO0464), and the Asian Institute of Gastroenterology (SA-PO0650). Together, they show nephrologists and researchers adopting the GalD Assay® and finding Gd-IgA1 to be a meaningful measure in their own work.

Gd-IgA1 is the central component involved in the formation of pathogenic immune complexes in IgAN. The 2025 KDIGO Clinical Practice Guideline for the Management of IgAN calls for treatments proven to reduce pathogenic forms of IgA, which are commonly measured as Gd-IgA1. With targeted therapies now approved or in late-stage clinical trials, researchers need a consistent, reproducible way to measure this biomarker. Gd-IgA1 measurement has long been complicated by variability between labs and methods, and the GalD Assay® was developed to address that challenge. *The GalD Assay® is for Research Use Only (RUO) and not for use in diagnostic procedures.*

> *"Kidney Week is the world's premier nephrology meeting, and this year research teams at four institutions and the CureGN consortium are presenting Gd-IgA1 work done with the GalD Assay®. That matters to us. We built this assay so researchers could measure Gd-IgA1 consistently, from lab to lab and study to study. Seeing nephrologists and research groups choose it for their own studies tells us the field sees real value in measuring Gd-IgA1, and it encourages us to keep expanding access to the assay worldwide."*
> **– Matthew Renfrow, PhD, CEO**

The GalD Assay® is being used by research laboratories both domestically and internationally, and Reliant Glycosciences remains focused on expanding access to the GalD Assay® through partnerships with clinical and research laboratories worldwide, and on building the body of evidence behind Gd-IgA1 measurement in IgAN. Reliant was founded on the conviction that better assays lead to better outcomes for patients with IgA nephropathy. Kidney Week attendees are invited to visit the Reliant Glycosciences team at Booth 1010 in the exhibit hall.

© 2026 Reliant Glycosciences, LLC · Birmingham, Alabama

CONFERENCE ABSTRACT ANNOUNCEMENT
American Society of Nephrology (ASN) Kidney Week 2026 · Denver, CO · October 21–25, 2026

Find Us at Kidney Week 2026

Conference	ASN Kidney Week 2026
Location	Colorado Convention Center, Denver, CO
Dates	October 21–25, 2026 (Annual Meeting October 22–25)
Booth	Reliant Glycosciences, Booth 1010
Poster	TH-PO0462 · Exhibit Hall A
Poster Date	Thursday, October 22, 2026
Time	10:00 AM – 12:00 PM U.S. Mountain Time

POSTER TITLE

Increase in Serum Galactose-Deficient IgA1 Level Measured by New Lectin-ELISA Predicts Progression to Kidney Failure in Adults with IgA Nephropathy

Gd-IgA1 at Kidney Week

Research teams at four institutions and the CureGN multicenter consortium are presenting Gd-IgA1 studies at Kidney Week 2026. A full list of Gd-IgA1 posters, booths, and talks is available on Reliant's Kidney Week notecard, at Booth 1010, and at reliantglycosciences.com.

ABOUT RELIANT GLYCOSCIENCES

Reliant Glycosciences, LLC is a Birmingham, Alabama-based biotechnology company founded in 2015 as a start-up from the University of Alabama at Birmingham. The company was established to commercialize breakthrough research from the laboratory of Dr. Jan Novak and colleagues, whose team identified the role of galactose-deficient IgA1 (Gd-IgA1) and disease-specific autoantibodies in the pathogenesis of IgA nephropathy. Reliant Glycosciences developed the GalD Assay®, a quantitative biomarker tool designed to support IgA nephropathy research, disease monitoring, and the advancement of targeted therapies. The team at Reliant Glycosciences brings together leading experts in biochemistry, nephrology, and assay development, united by a commitment to improving patient outcomes in IgA nephropathy.

For more information, contact:
Tatum Moss, MBA
Reliant Glycosciences
www.reliantglycosciences.com

Better assays. Better outcomes.

© 2026 Reliant Glycosciences, LLC · Birmingham, Alabama